MX2022004255A - Composicion farmaceutica que comprende mitotano para la administracion oral para el tratamiento del carcinoma adrenocortical y el sindrome de cushing. - Google Patents

Composicion farmaceutica que comprende mitotano para la administracion oral para el tratamiento del carcinoma adrenocortical y el sindrome de cushing.

Info

Publication number
MX2022004255A
MX2022004255A MX2022004255A MX2022004255A MX2022004255A MX 2022004255 A MX2022004255 A MX 2022004255A MX 2022004255 A MX2022004255 A MX 2022004255A MX 2022004255 A MX2022004255 A MX 2022004255A MX 2022004255 A MX2022004255 A MX 2022004255A
Authority
MX
Mexico
Prior art keywords
cushing
mitotane
syndrome
treatment
adrenocortical carcinoma
Prior art date
Application number
MX2022004255A
Other languages
English (en)
Inventor
Mohamed Skiba
Malika Lahiani-Skiba
Frédéric Bounoure
Michael Thomas
Hervé Lefebvre
Original Assignee
Mohamed Skiba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mohamed Skiba filed Critical Mohamed Skiba
Publication of MX2022004255A publication Critical patent/MX2022004255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un objeto de la presente invención es la preparación y uso de una nueva emulsión seca (DE), que contiene mitotano y su uso para la ruta oral para el tratamiento del carcinoma adrenocortical, la hiperplasia adrenal congénita y el síndrome de Cushing.
MX2022004255A 2019-10-28 2020-10-01 Composicion farmaceutica que comprende mitotano para la administracion oral para el tratamiento del carcinoma adrenocortical y el sindrome de cushing. MX2022004255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1912084A FR3102356B1 (fr) 2019-10-28 2019-10-28 Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing
PCT/IB2020/059218 WO2021084345A1 (fr) 2019-10-28 2020-10-01 Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing

Publications (1)

Publication Number Publication Date
MX2022004255A true MX2022004255A (es) 2022-05-06

Family

ID=69810998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004255A MX2022004255A (es) 2019-10-28 2020-10-01 Composicion farmaceutica que comprende mitotano para la administracion oral para el tratamiento del carcinoma adrenocortical y el sindrome de cushing.

Country Status (16)

Country Link
US (1) US20240058277A1 (es)
EP (1) EP4051249B1 (es)
JP (1) JP2023500494A (es)
KR (1) KR20220088904A (es)
CN (1) CN114599347A (es)
AU (1) AU2020377140A1 (es)
CA (1) CA3153794A1 (es)
ES (1) ES2966481T3 (es)
FR (1) FR3102356B1 (es)
HR (1) HRP20231641T1 (es)
HU (1) HUE064738T2 (es)
MX (1) MX2022004255A (es)
PL (1) PL4051249T4 (es)
RS (1) RS64962B1 (es)
WO (1) WO2021084345A1 (es)
ZA (1) ZA202205923B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146648A (en) * 1977-07-14 1979-03-27 Bristol-Myers Company Chemotherapeutic composition
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
DE602007002905D1 (de) * 2006-01-23 2009-12-03 Yissum Res Dev Co Mikrokügelchen mit nanokapseln, die ein lipophiles arzneimittel enthalten
EP2255786A1 (en) 2009-05-25 2010-12-01 HRA Pharma LLC Self-microemulsifying mitotane composition
US20130317117A1 (en) 2010-11-24 2013-11-28 Pharmaceutics International, Inc. Self micro-emulsifying drug delivery system with increased bioavailability
CN105250221B (zh) * 2014-07-14 2018-06-19 天津药物研究院 一种利可瑞特干乳剂及其制备方法

Also Published As

Publication number Publication date
ZA202205923B (en) 2023-04-26
WO2021084345A1 (fr) 2021-05-06
KR20220088904A (ko) 2022-06-28
EP4051249C0 (fr) 2023-09-13
CA3153794A1 (en) 2021-05-06
AU2020377140A1 (en) 2022-06-09
JP2023500494A (ja) 2023-01-06
US20240058277A1 (en) 2024-02-22
ES2966481T3 (es) 2024-04-22
FR3102356B1 (fr) 2021-09-17
PL4051249T3 (pl) 2024-04-08
FR3102356A1 (fr) 2021-04-30
PL4051249T4 (pl) 2024-04-08
EP4051249B1 (fr) 2023-09-13
RS64962B1 (sr) 2024-01-31
HUE064738T2 (hu) 2024-04-28
HRP20231641T1 (hr) 2024-03-15
EP4051249A1 (fr) 2022-09-07
CN114599347A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
JP2016512248A5 (es)
MX367358B (es) Composiciones farmaceuticas que comprenden azd9291.
MX2017016274A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol.
SA517390550B1 (ar) وحدة جرعة قابلة للتفتت في الفم تتضمن مكون أستيترول
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
JP2014111664A5 (es)
JP2020536965A5 (es)
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
JP2009505991A5 (es)
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
JP2016512247A5 (es)
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
MX2022004255A (es) Composicion farmaceutica que comprende mitotano para la administracion oral para el tratamiento del carcinoma adrenocortical y el sindrome de cushing.
MX2022001802A (es) Metodos para incrementar la biodisponibilidad de medicamentos farmaceuticos y de venta libre.
PH12017501831A1 (en) Pharmaceutical compositions for oral administration
MX2022002555A (es) Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres.
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
JP6838474B2 (ja) 固形組成物
JP2017515858A5 (es)
MX2017012633A (es) Proceso para la fabricación de mezclas de polvo seco.
MX2021000312A (es) Composicion farmaceutica que contiene un peptido.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.